{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:52:43Z","timestamp":1770511963937,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Medical University of Lodz, Poland","award":["503\/8-093-01\/503-01"],"award-info":[{"award-number":["503\/8-093-01\/503-01"]}]},{"name":"Medical University of Lodz, Poland","award":["503\/1-093-01\/503-01"],"award-info":[{"award-number":["503\/1-093-01\/503-01"]}]}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ejca.2014.07.021","type":"journal-article","created":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T22:15:21Z","timestamp":1408400121000},"page":"2677-2684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies"],"prefix":"10.1016","volume":"50","clinical-trial-number":[{"clinical-trial-number":"nct01188681","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01317901","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Piotr","family":"Smolewski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Robak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Cebula-Obrzut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Misiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"M\u0119dra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Majchrzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Witkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Stromatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2014.07.021_b0005","first-page":"1383","article-title":"TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies","volume":"10","author":"Robak","year":"2009","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.ejca.2014.07.021_b0010","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2860.2860","article-title":"Phase 2 study of otlertuzumab (TRU-016), an anti-cd37 ADAPTIR\u2122 protein, in combination with bendamustine vs bendamustine alone in patients with relapsed chronic lymphocytic leukemia (CLL)","author":"Robak","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2014.07.021_b0015","first-page":"886","article-title":"Novel agents for the treatment of chronic lymphocytic leukemia","volume":"8","author":"Abou-Nassar","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ejca.2014.07.021_b0020","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.23491","article-title":"Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment","author":"Hallek","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2014.07.021_b0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2217\/fon.12.157","article-title":"Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia","volume":"9","author":"Robak","year":"2013","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2014.07.021_b0030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.hoc.2012.12.003","article-title":"Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy","volume":"27","author":"Stephens","year":"2013","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.ejca.2014.07.021_b0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/2040620712458949","article-title":"Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use","volume":"3","author":"Warner","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.ejca.2014.07.021_b0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/2040620712445329","article-title":"Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia","volume":"3","author":"Dyer","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.ejca.2014.07.021_b0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1749-6632.2012.06661.x","article-title":"Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies","volume":"1263","author":"Gupta","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejca.2014.07.021_b0050","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.ejca.2014.07.021_b0055","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"6","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2014.07.021_b0060","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ccr.2012.04.034","article-title":"SMIP-016 in action: CD37 as a death receptor","volume":"21","author":"Jin","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2014.07.021_b0065","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","article-title":"Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals","volume":"21","author":"Lapalombella","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2014.07.021_b0070","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1182\/blood-2011-04-351932","article-title":"A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies","volume":"118","author":"Heider","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2014.07.021_b0075","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","article-title":"Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical","volume":"6","author":"Zhao","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2014.07.021_b0080","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2012-12-472027","article-title":"Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma","volume":"122","author":"Matasar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2014.07.021_b0085","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/leu.2011.233","article-title":"Action of novel CD37 antibodies on chronic lymphocytic leukemia cells","volume":"26","author":"Krause","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2014.07.021_b0090","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","article-title":"Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study","volume":"119","author":"Czuczman","year":"2012","journal-title":"Blood"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914008739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914008739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T12:48:54Z","timestamp":1598186934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914008739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0959804914008739"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.07.021","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}